Product Description
Camicinal (GSK962040) is the most advanced, small-molecule, selective motilin receptor agonist with therapeutic potential to date. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25341626/)
Mechanisms of Action: Motilin receptor Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Gastroparesis|Parkinson's Disease
Phase 1: Gastroparesis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT01934192 | P2 |
Terminated |
Gastroparesis |
2016-07-08 |
|
NCT02210000 | P2 |
Completed |
Gastroparesis |
2015-08-24 |
|
GSK962040 Parkinson's disease PoC | P2 |
Completed |
Parkinson's Disease |
2014-05-01 |
|
NCT01602549 | P2 |
Completed |
Gastroparesis|Parkinson's Disease |
2014-05-01 |